Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,753 Mln
P/E Ratio
--
P/B Ratio
56.59
Industry P/E
--
Debt to Equity
-0.03
ROE
-19.25 %
ROCE
254.2 %
Div. Yield
0 %
Book Value
--
EPS
-0.43
CFO
$-864.76 Mln
EBITDA
$-966.64 Mln
Net Profit
$-1,284.74 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
BioCryst Pharmaceuticals (BCRX)
| 10.64 | 6.26 | 3.87 | 100.00 | -5.79 | 18.57 | -1.78 |
|
BSE Sensex*
| 2.73 | 3.84 | 5.91 | 9.03 | 11.80 | 20.14 | 11.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
BioCryst Pharmaceuticals (BCRX)
| 25.31 | -47.82 | -17.11 | 85.91 | 115.94 | -57.25 | 63.91 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.44 | 10,315.11 | 21.27 | 23.13 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 27.46 | 10,589.59 | -- | -28.77 | |
| 106.46 | 10,559.67 | 32.44 | 14.16 |
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of... acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Address: 4505 Emperor Boulevard, Durham, NC, United States, 27703 Read more
CEO, President & Executive Director
Mr. Jon P. Stonehouse
CEO, President & Executive Director
Mr. Jon P. Stonehouse
Headquarters
Durham, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of BioCryst Pharmaceuticals Inc (BCRX) stood at $ 490 Mln as on 31-Dec-24
The share price of BioCryst Pharmaceuticals Inc (BCRX) is $8.32 (NASDAQ) as of 28-Apr-2025 16:28 EDT. BioCryst Pharmaceuticals Inc (BCRX) has given a return of -5.79% in the last 3 years.
BioCryst Pharmaceuticals Inc (BCRX) has a market capitalisation of $ 1,753 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of BioCryst Pharmaceuticals Inc (BCRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the BioCryst Pharmaceuticals Inc (BCRX) and enter the required number of quantities and click on buy to purchase the shares of BioCryst Pharmaceuticals Inc (BCRX).
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Address: 4505 Emperor Boulevard, Durham, NC, United States, 27703
The CEO & director of Mr. Jon P. Stonehouse. is BioCryst Pharmaceuticals Inc (BCRX), and CFO & Sr. VP is Mr. Jon P. Stonehouse.
There is no promoter pledging in BioCryst Pharmaceuticals Inc (BCRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| BioCryst Pharmaceuticals Inc. (BCRX) | Ratios |
|---|---|
|
Return on equity(%)
|
19.08
|
|
Operating margin(%)
|
2.57
|
|
Net Margin(%)
|
-19.72
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of BioCryst Pharmaceuticals Inc (BCRX) was $0 Mln.
$-0.07
(
